Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

被引：2
|
作者：
Kienle, D. [1 ]
Winterhalder, R. [2 ]
Koeberle, D. [3 ]
Horber, D. [4 ]
Kueng, M. [5 ]
Saletti, P. [6 ]
Helbling, D. [7 ]
Bastian, S. [8 ]
Dietrich, D. [9 ]
Baertschi, D. [9 ]
Pilop, C. [9 ]
Von Moos, R. [8 ]
机构：
[1] Stadtspital Triemli, Haematol & Med Oncol, Zurich, Switzerland
[2] Kantonsspital Luzern, Med Oncol, Luzern, Switzerland
[3] Claraspital Basel, Oncol, Basel, Switzerland
[4] Kantonsspital St Gallen, Oncol Haematol, St Gallen, Switzerland
[5] HFR, Med Oncol, Fribourg, Switzerland
[6] Oncol Inst Southern Switzerland, Med Oncol, Bellinzona, Switzerland
[7] OnkoZentrum Klin Pk, Oncol, Zurich, Switzerland
[8] Kantonsspital Graubuenden, Oncol Haematol, Chur, Switzerland
[9] Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30565-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1322
引用
收藏
页码：S194 / S195
页数：2
相关论文
共 50 条
  • [41] Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial
    Aranda, E.
    Ia-Alfonso, P. Garc '
    Benavides, M.
    Sanchez-Ruiz, A.
    Guillen-Ponce, C.
    Safont, M. J.
    Alcaide, J.
    Gomez, A.
    Lopez, R.
    Manzano, J. L.
    Mendez-Urena, M.
    Lopez, C.
    Garcia-Paredes, B.
    Gravalos, C.
    Garcia-Garcia, T.
    Falco, E.
    Martin-Valades, J. I.
    Gonzalez-Flores, E.
    Navalon, M.
    Diaz-Rubio, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S371 - S372
  • [42] Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI plus cetuximab until disease progression compared to FOLFIRI plus cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
    Pinto, Carmine
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Bilancia, Domenico
    Corsi, Domenico C.
    Tamburini, Emiliano
    Pisconti, Salvatore
    Ferrau, Francesco
    Di Costanzo, Francesco
    Gori, Stefania
    Daniele, Bruno
    Tonini, Giuseppe
    Zaniboni, Alberto
    Soto-Parra, Hector
    Frassinetti, Giovanni Luca
    Iaffaioli, Rosario Vincenz
    Zampino, M. Giulia
    Repetto, Lazzaro
    Barone, Carlo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Triplet chemotherapy plus cetuximab as first -line treatment in RAS wild -type metastatic colorectal carcinoma patients
    Samalin, E.
    Mazard, T.
    Assenat, E.
    Rouyer, M.
    De la Fouchardiere, C.
    Guimbaud, R.
    Smith, D.
    Portales, F.
    Ychou, M.
    Fiess, C.
    de Forges, H.
    Lopez-Crapez, E.
    Thezenas, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Ke, Tao-Wei
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Hsuan-Yuan
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
  • [45] Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
    Liu, Yue
    Xiao, Qian
    He, Jinjie
    Hu, Hanguang
    Du, Jinlin
    Zhu, Yuping
    Chen, Jiaqi
    Liu, Zhuo
    Wang, Jianping
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Liao, Xiujun
    Wang, Jianwei
    Cai, Yibo
    Cai, Cheng
    Jin, Zhekang
    Wang, Liuhong
    Yuan, Ying
    Ding, Kefeng
    BMC MEDICINE, 2022, 20 (01)
  • [46] Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
    Yue Liu
    Qian Xiao
    Jinjie He
    Hanguang Hu
    Jinlin Du
    Yuping Zhu
    Jiaqi Chen
    Zhuo Liu
    Jianping Wang
    Lifeng Sun
    Dong Xu
    Jun Li
    Xiujun Liao
    Jianwei Wang
    Yibo Cai
    Cheng Cai
    Zhekang Jin
    Liuhong Wang
    Ying Yuan
    Kefeng Ding
    BMC Medicine, 20
  • [47] Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial
    Cremolini, Chiara
    Antoniotti, Carlotta
    Lonardi, Sara
    Aprile, Giuseppe
    Bergamo, Francesca
    Masi, Gianluca
    Grande, Roberta
    Tonini, Giuseppe
    Mescoli, Claudia
    Cardellino, Giovanni Gerardo
    Coltelli, Luigi
    Salvatore, Lisa
    Corsi, Domenico Cristiano
    Lupi, Cristiana
    Gemma, Donatello
    Ronzoni, Monica
    Dell'Aquila, Emanuela
    Marmorino, Federica
    Di Fabio, Francesca
    Mancini, Maria Laura
    Marcucci, Lorenzo
    Fontanini, Gabriella
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    JAMA ONCOLOGY, 2018, 4 (04) : 529 - 536
  • [48] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [49] The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK).
    Borner, M.
    Mingrone, W.
    Koeberle, D.
    Von Moos, R.
    Rauch, D.
    Saletti, P.
    Herrmann, R.
    Dietrich, D.
    Lanz, D.
    Roth, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [50] Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America
    Pescott, Chris
    Kasle, Adam
    Esteso, Federico
    Stefani, Stephen
    Brust, Leandro
    Pinto, Jose
    Tilli, Malena
    Massello, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345